Pipeline Overview
Our goal is to identify, develop, and commercialize the next generation of therapies for new treatments for cardiovascular diseases. Our approach is simple: by leveraging our significant scientific and medical resources, we identify and in-license premium drug candidates that we develop either independently or through soundly structured collaborations with external partners. We are currently building a balanced, robust and diverse portfolio of effective, targeted, new treatments to address unmet needs.

Our current compound in development

INDI-702
INDI-702 is in late-stage development seeking an indication for reduction of symptoms of intermittent claudication (IC) in patients with peripheral arterial disease. INDI-702 is in Phase III clinical development. Phase IIb/III study data with INDI-702 has been published in Journal of American College of Cardiology (J Am Col Cardiol 2006; 48:2539-45).